---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-263383"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:39:14.604072+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IDEAYA reports Q3 net income $119.2M, cash $1.14B; darovasertib partnership with Servier closed

## Summary
- Net income of $119.2M vs Q2 net loss of $77.5M; collaboration revenue $207.8M from Servier license.
- Cash, equivalents, marketable securities $1.14B (up from $991.9M Q2); funded into 2030.
- Darovasertib Phase 2/3 OptimUM-02 median PFS data due by year-end 2025 to Q1 2026; trial nearing full enrollment.
- IDE849 DLL3 ADC in SCLC: 80.0% ORR in 2L patients at 2.4 mg/kg; median PFS 6.7 months across all lines.
- IND clearance for IDE892 (PRMT5) in Q3; IND filed for IDE034 (bispecific ADC); IDE574 IND on track for year-end.

## SEC filing metadata
- accession: 0001193125-25-263383
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312525263383/0001193125-25-263383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312525263383/idya-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-263383
- JSON: https://secwatch.observer/filing/0001193125-25-263383.json
- Plain text: https://secwatch.observer/filing/0001193125-25-263383.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.